NEW YORK, May 16, 2017 /PRNewswire/ -- Attorney Advertising --
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intra-Cellular
Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ITCI) and certain of its officers, on behalf of shareholders who
purchased Intra-Cellular securities between August 12, 2014 and April 28,
2017, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the
firm's site: http://www.bgandg.com/itci.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the
Securities Exchange Act of 1934.
The Complaint states that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to
disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings
posed an additional safety concern regarding lumateperone; and (3) consequently, Intra-Cellular's public statements were
materially false and misleading at all relevant times.
On August 4, 2016, Intra-Cellular's CEO Sharon Mates specified
during an earnings call that "our studies to-date supports the efficacy and safety of ITI-007 for the treatment of
schizophrenia." Then on May 1, 2017, Intra-Cellular revealed that U.S. Food and Drug Administration
had requested further information to verify that the findings observed in nonclinical animal toxicology studies of lumateperone
are not suggestive of a safety risk associated with long term exposure in humans. Following this news, Intra-Cellular stock
dropped.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site:
http://www.bgandg.com/itci or you may contact
Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Intra-Cellular you have until
July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share
in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive
pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as
well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-intra-cellular-therapies-inc-itci-and-lead-plaintiff-deadline-july-11-2017-300458219.html
SOURCE Bronstein, Gewirtz & Grossman, LLC